亲溶酶体药物IHW_2和IHW_3对急性髓细胞白血病细胞体外净化的研究  

IN VITRO TREATMENT OF AML CELLS WITH LYSOSOMOTROPIC AGENT IHW_2 AND IHW_3

作　　者：徐国珠[1] 姜容[1] 王军[1] 赵英新[1] 严文伟[1] 郝玉书[1] 

机构地区：[1]中国医学科学院协和医科大学血液学研究所

出　　处：《中华血液学杂志》1994年第5期233-235,共3页Chinese Journal of Hematology

摘　　要：ＩＨＷ＿２和ＩＨＷ＿３是亲溶酶体药物十二烷基吗啉（ＮＤＭ）的类似物。由于分子中引入了亲水基团，所以是水溶性药物，较ＮＤＭ更容易经胞饮作用进入富含溶酶体的白血病细胞，破坏溶酶体，从而导致细胞的死亡。ＩＨＷ＿２和ＩＨＷ＿３用量为８５μｇ／１×１０￣７和４２μｇ／１×１０￣７细胞时，，几乎能杀灭１００％的白血病细胞，同时保留１９．４±１６．５％和７．９±１２．７％的正常造血干细胞。ＩＨＷ＿３净化急性髓细胞白血病细胞的作用比ＩＨＷ＿２强约１倍。ＩＨＷ＿２和ＩＨＷ＿３有希望用于临床体外净化ＡＭＬ细胞。HW_2 and IHW_3 were analogues of lysosomotropic agent N--dodecylmorpholine.Due to hydrophilic group they were soluble in water,and by pinocytosis easier enterinto lysosomes of leukemic cells,so as the lysosomes membrane rupured and the cells werekilled.Mean while 19.4±16.5% and 7.9±12.7% of normal stem cells were remained.The purging effect of IHW_3 was higher(1x) than IHW_2.So there will be possiblity touse IHW_2 and IHW_3 clinically for in vitro purging AML cells.

关 键 词：亲溶酶体药物 骨髓移植 白血病 

分 类 号：R733.705[医药卫生—肿瘤]